0001415889-24-014451.txt : 20240524 0001415889-24-014451.hdr.sgml : 20240524 20240524161004 ACCESSION NUMBER: 0001415889-24-014451 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240522 FILED AS OF DATE: 20240524 DATE AS OF CHANGE: 20240524 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Yea Christopher CENTRAL INDEX KEY: 0001691102 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36830 FILM NUMBER: 24984375 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE, BUILDING 200 STREET 2: SUITE 2203 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: KalVista Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001348911 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 200915291 STATE OF INCORPORATION: DE FISCAL YEAR END: 0430 BUSINESS ADDRESS: STREET 1: 55 CAMBRIDGE PARKWAY STREET 2: SUITE 901E CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (857) 999-0075 MAIL ADDRESS: STREET 1: 55 CAMBRIDGE PARKWAY STREET 2: SUITE 901E CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Therapeutics, Inc. DATE OF NAME CHANGE: 20140916 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Biosurgery, Inc DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Biosurgery Inc DATE OF NAME CHANGE: 20060105 4 1 form4-05242024_080552.xml X0508 4 2024-05-22 0001348911 KalVista Pharmaceuticals, Inc. KALV 0001691102 Yea Christopher C/O KALVISTA PHARMACEUTICALS, INC 55 CAMBRIDGE PARKWAY, SUITE 901E CAMBRIDGE MA 02142 false true false false CHIEF DEVELOPMENT OFFICER 0 Restricted Stock Units 2024-05-22 4 A 0 50000 0 A Common Stock 50000 50000 D Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. 1/16th of the total RSUs subject to the Award shall vest on each quarterly anniversary of the vesting commencement date, commencing on August 22, 2024, until fully vested, subject to continued service through each vesting date. /s/ Benjamin L. Palleiko, Attorney-in-Fact 2024-05-24